

RESEARCH

Open Access

# Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy

Manabu Natsumeda<sup>1</sup>, Hironaka Igarashi<sup>2\*</sup>, Toshiharu Nomura<sup>1</sup>, Ryosuke Ogura<sup>1</sup>, Yoshihiro Tsukamoto<sup>1</sup>, Tsutomu Kobayashi<sup>1</sup>, Hiroshi Aoki<sup>1</sup>, Kouichirou Okamoto<sup>1</sup>, Akiyoshi Kakita<sup>3</sup>, Hitoshi Takahashi<sup>3</sup>, Tsutomu Nakada<sup>2</sup> and Yukihiko Fujii<sup>1</sup>

## Abstract

**Introduction:** Previous magnetic resonance spectroscopy (MRS) and mass spectroscopy studies have shown accumulation of 2-hydroxyglutarate (2HG) in mutant isocitrate dehydrogenase (*IDH*) gliomas. *IDH* mutation is known to be a powerful positive prognostic marker in malignant gliomas. Hence, 2HG accumulation in gliomas was assumed to be a positive prognostic factor in gliomas, but this has not yet been proven. Here, we analyzed 52 patients harboring World Health Organization (WHO) grade II and III gliomas utilizing 3.0-tesla MRS.

**Results:** Mutant *IDH* gliomas showed significantly higher accumulation of 2HG (median 5.077 vs. 0.000,  $p = 0.0002$ , Mann-Whitney test). 2HG was detectable in all mutant *IDH* gliomas, whereas in 10 out of 27 (37.0%) wild-type *IDH* gliomas, 2HG was below the detectable range (2HG = 0) ( $p = 0.0003$ , chi-squared test). Screening for *IDH* mutation by 2HG analysis was highly sensitive (cutoff 2HG = 1.489 mM, sensitivity 100.0%, specificity 72.2%). Gliomas with high 2HG accumulation had better overall survival than gliomas with low 2HG accumulation ( $p = 0.0401$ , Kaplan-Meier analysis).

**Discussion:** 2HG accumulation detected by 3.0-tesla MRS not only correlates well with *IDH* status, but also positively correlates with survival in WHO grade II and III gliomas.

**Keywords:** Glioma, MRS, 2-hydroxyglutarate, *IDH* mutation, Prognostic marker

## Introduction

A comprehensive genomic analysis of glioblastomas has shown that mutations of isocitrate dehydrogenase (*IDH*) are found in a subset of glioblastoma [1], and subsequent studies have found *IDH* mutation to be a powerful prognostic factor in malignant gliomas [2], suggesting that *IDH* mutations represent a clinically distinct subset of gliomas. The accumulation of 2-hydroxyglutarate (2HG) is noted in the cytoplasm of glioma cells with *IDH1* mutation and in the mitochondria of cells with *IDH2* mutation (Figure 1) [3]. Magnetic resonance spectroscopy (MRS) [4-10] as well as mass spectrometry [3,10-12] are known to effectively measure 2HG in glioma tissues with good correlations to *IDH* mutation status. 2HG is an oncometabolite,

which has been shown to cause tumorigenesis by inhibition of histone demethylation [13-15] and DNA demethylation [16,15]. 2HG accumulation in gliomas was assumed to positively correlate with patient survival because of the correlation of *IDH* status to patient survival in malignant gliomas. However, to date, this has not been proven. In the present study, 2HG accumulation was shown to have a positive correlation with overall patient survival in WHO grade II and III gliomas for the first time.

## Materials and methods


### Participants

Seventy-one adult patients harboring World Health Organization (WHO) grade II or III gliomas, receiving magnetic resonance spectroscopy (MRS) evaluation at the Center for Integrated Brain Science, University of Niigata, before surgery and surgical treatment at the Department of Neurosurgery, University of Niigata,

\* Correspondence: [higara@bri.niigata-u.ac.jp](mailto:higara@bri.niigata-u.ac.jp)

<sup>2</sup>Center for Integrated Brain Sciences, Brain Research Institute, University of Niigata, Niigata, Japan

Full list of author information is available at the end of the article



**Figure 1** Schematic representation of 2HG production in *IDH* mutant gliomas. Accumulation of 2HG is seen in the cytoplasm of mutant *IDH1* and mitochondria of mutant *IDH2* gliomas. 2HG is also derived from glutamine in mutant *IDH* gliomas.

from December 2006 to March 2013 were included in the study. Patients with non-astrocytic, non-oligodendroglial, and non-oligoastrocytic tumors (e.g. ependymomas,  $n = 11$ ), patients whose MRS scans had low signal-to-noise ratios (S/N) of less than 4 ( $n = 4$ ), patients having a glioblastoma-like single voxel MRS (SVMRS) spectra at relapse reflecting radiation necrosis or malignant transformation ( $n = 2$ ), a patient harboring a cystic lesion with insufficient volume of a solid component ( $n = 1$ ), and a patient lost to follow up ( $n = 1$ ), were excluded from the analysis. Thus, a total of 52 patients were ultimately analyzed. Written informed consent was obtained from all of the participants in accordance with the human research guidelines of the Internal Review Board of University of Niigata.

#### MRS analysis

MRI/ $^1\text{H}$ -MRS was performed using a 3.0-tesla system (Signa LX, General Electric, Waukesha, WI) with an 8 channel phased array coil head. First, proton density images (Fast Spin Echo; TR/TE = 5000/40; FOV: 20 × 20 mm; matrix: 256 × 256; slice thickness: 5 mm; inter slice gap: 2.5 mm) were taken. The slice with the largest depiction of tumor on proton density images was selected for SVMRS. A point-resolved spectroscopic sequence (PRESS), with chemical-shift-selective water suppression was used with the following parameters: (TR: 1.5 s; TE: 30 ms; data point 512; spectral width 1000Hz; number of acquisitions: 128–196; volume of interest (VOI): 12–20 × 12–20 × 12–20 mm).

Spectral analysis was performed using LCModel version 6.3 (Stephen Provencher, Oakville, Ontario, Canada) [17]. This software automatically adjusts the phase and chemical shift of the spectra, estimates the baseline, and performs eddy current corrections. Relative metabolite concentrations and their uncertainties were estimated by

fitting the spectrum to a basis set of spectra acquired from individual metabolites in solution. The basis set was made with MR experiment simulation software (GAMMA, Radiology, Duke University Medical Center, Durham, NC) and provided by Dr. Steven Provencher [17] and was calibrated with MRS phantom solution (18-cm-diameter MRS HDsphere, model 2152220; General Electric, Milwaukee, WI) using our MR system. Nineteen metabolites were included in this LCModel basis set: alanine, aspartate, creatine (Cr), phosphocreatine (PCr),  $\gamma$ -aminobutyric acid, glucose, glutamine (Gln), glutamate (Glu), glycerophosphocholine (GPC), phosphocholine (PC), glutathione (GSH), 2-hydroxyglutarate (2HG), myo-inositol (Ins), lactate, NAA (N-acetylaspartate), N-acetylaspartylglutamate (NAAG), scyllo-inositol, taurine, and guanine. Total NAA (tNAA: the sum of NAA and NAAG), total choline (tCho: the sum of GPC and PC), total creatine (tCr: the sum of Cr and PCr), and sum of Glu and Gln (Glx) were noted. To calculate the absolute metabolite concentrations, an un-suppressed water signal was used as a reference.

Quantification estimates of metabolites were considered unreliable and excluded when Cramer-Rao lower bounds, returned as the percentage of standard deviation (%SD) by LCModel, was greater than 35%, as previously described [18]. Because low 2HG and GSH estimates yielded large %SDs (i.e. when 2HG = 0, %SD =  $\infty$ ), the above exclusion criteria was applied only when the estimated 2HG amount was greater than 1.0 mM or GSH was greater than 0.5 mM. Glx and tNAA were excluded when %SD was greater than 30%; tCho and tCr were excluded when %SD was greater than 20%.

#### Pathological analysis and IDH analysis

Surgical specimens were analyzed by two pathologists (H.T. and A.K.) and diagnosed according to the WHO

classification [19]. IDH1 R132H immunohistochemical (IHC) analysis (H09 clone, Dianova, Hamburg, Germany; 1:100) was performed in formalin-fixed, paraffin imbedded section using the avidin-biotin-peroxide method (Vector, Burlingame, CA, USA) with diaminobenzidine as the chromogen and counterstained with hematoxylin.

For cases showing negative staining for IDH1 R132H, DNA sequencing for *IDH1* and *IDH2* was analyzed. Genomic DNA was extracted from paraffin-embedded sections, and as described previously [20,21], PCR amplification was performed by using primer sets (forward: 5'-CGGTCTTCAGAGAAGCCATT-3', and reverse 5'-TT CATACTTGCTTAATGGGTGT-3') at codon 132 for the *IDH1* gene and (forward: 5'-AATTTTAGGACCCC CGTCTG-3', and reverse 5'-CTGCAGAGACAAGAGG ATGG-3') at codon 172 for the *IDH2* gene. The PCR products were then sequenced on a 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) with a Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) in accordance with the manufacturer's instructions.

### Statistical analysis

Corrected metabolite concentrations of patients harboring mutant *IDH* gliomas were compared to those harboring gliomas of wild-type *IDH* using the Mann-Whitney U test. Receiver operating characteristic (ROC) curve was used to determine a cutoff for 2HG concentration to obtain maximal sensitivity and specificity to identify *IDH* mutations. Kaplan-Meier analysis was used to compare overall survival. Tests for associations between different parameters were carried out by the chi-squared test for 2 × 2 contingency tables.  $p < 0.05$  was considered significant. Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, <http://www.graphpad.com>).

### Results

A summary of the patient characteristics of mutant and wild-type *IDH* groups is provided in Table 1. Median patient age was 53 years; Patients harboring mutant *IDH* gliomas were younger than those with wild-type *IDH* gliomas (45 years vs. 61 years,  $p = 0.0008$ , Mann-Whitney U test). A majority (90.4%) of the patients analyzed were newly-diagnosed patients. *IDH* mutations were found in only 25 out of 52 cases (48.1%), this was probably due to: the inclusion of primary glioblastoma and glioblastoma with oligodendroglioma component, failure to detect rare *IDH1* and *IDH2* mutations by DNA sequencing, and/or selection bias due to the preoperative availability of MRS. There were more WHO grade II tumors (68.0% vs. 25.9%,  $p = 0.0024$ ) and more patients were alive at last follow-up in the mutant *IDH* group (80.0% vs. 44.4%,  $p = 0.0085$ ).

Representative SVMRS spectra of mutant *IDH* and wild-type *IDH* gliomas are provided in Figure 2. Small

**Table 1 Patient characteristics of mutant and wild-type *IDH* groups**

Characteristic	Number of patients (%)		p value
	Mutant <i>IDH</i>	Wild-type <i>IDH</i>	
Number	25	27	
Men: Women	14:11	14:13	
Age (years)			
Median	45	61	0.0008*
Range	26-67	28-77	
Newly diagnosed	22 (88.0)	25 (92.6)	0.9279
Recurrent	3 (12.0)	2 (7.4)	
Pathological grade			
WHO Grade II	17 (68.0)	7 (25.9)	0.0024*
WHO Grade III	8 (32.0)	20 (74.1)	
Outcome			
Alive	20 (80.0)	12 (44.4)	0.0085*
Dead	5 (20.0)	15 (55.6)	

Results of unpaired t-test (age) and chi-squared tests (others). The values inside parentheses represent percentage of patients within each group.


\* $p < 0.05$ .

IDH: isocitrate dehydrogenase; WHO: World Health Organization.

peaks were detected at a chemical shift of about 2.25 ppm in mutant *IDH* gliomas. Both spectra have similar choline peaks, but these were not adjusted for choline.

Mutant *IDH* gliomas showed a significantly higher accumulation of 2HG (median 5.077 mM vs. 0.000 mM,  $p = 0.0002$ , Mann-Whitney test). Mutant *IDH* gliomas also showed lower levels of GSH (median 1.849 vs. 2.409,  $p = 0.0328$ ) and Glx (median 7.701 vs. 9.528,  $p = 0.001$ ) compared to the wild-type *IDH* gliomas (Figure 3A). Levels of Ins, tNAA, tCho, and tCr were not significantly different between the two groups.

ROC curve analysis obtained a cutoff of 2HG = 1.489 mM, with a sensitivity of 100.0% and specificity of 72.2%, to detect *IDH* mutations (Figure 3B). 2HG was detectable in all mutant *IDH* gliomas, whereas in 10 out of 27 (37.0%) wild-type *IDH* gliomas, 2HG was not detectable (2HG = 0) ( $p = 0.0003$ ). Five (18.5%) of the wild-type *IDH* gliomas had an accumulation of 2HG higher than 1.489 mM; three gliomas (11.1%) yielded a concentration of 2HG higher than 5 mM (Figure 3B). A significantly longer overall patient survival was noted in gliomas with high accumulation of 2HG ( $p = 0.0401$ , Figure 4). Median survival was 823 days in glioma patients with low 2HG; median patient survival was not reached in the glioma patients with high 2HG. There was no significant difference in survival between patients harboring wild-type *IDH* glioma patients with high 2HG accumulation (2HG > 1.489 mM) vs. low 2HG accumulation ( $p = 0.4894$ , Kaplan-Meier curves not shown). Likewise there was no significant difference in survival between mutant *IDH* gliomas with high 2HG



**Figure 2 SVMRS spectra of mutant *IDH* and wild-type *IDH* gliomas.** Representative SVMRS spectra of mutant *IDH* (red) and wild-type *IDH* gliomas (blue) are shown. Small peaks were detected at a chemical shift of about 2.25 ppm in mutant *IDH* gliomas. Both spectra have similar choline peaks, but these were not adjusted for choline.

accumulation (2HG >5.077 mM) vs. low 2HG accumulation ( $p = 0.8815$ , Additional file 1: Figure S1), although median survival has not been reached in either group.

## Discussion


IDH1 and IDH2 enzymes catalyze oxidative decarboxylation of isocitrate to  $\alpha$ -ketoglutarate ( $\alpha$ -KG). Mutant IDH cannot catalyze this reaction and instead reduces  $\alpha$ -KG to 2HG [3] (Figure 1). 2HG is oxidized by 2-hydroxyglutarate dehydrogenase (2-HGDH) back to  $\alpha$ -KG, and the mutation of 2-HGDH is known to cause 2-hydroxyglutaric aciduria [22]. A previous study has shown that glutamate is the main source of carbons for 2HG in mutant *IDH* glioma cells [3].

In our study, 2HG was detected in all mutant *IDH* gliomas. On the other hand, in a subset of wild-type *IDH* gliomas, a high 2HG concentration was noted (Figure 3B). This may be attributed to false-positive results [23] or a failure to detect rare *IDH1* or *IDH2* mutations by DNA


sequencing. However, a recent study showed millimolar concentrations of 2HG in wild-type *IDH* breast cancer tissues. These accumulations were found to be associated with *MYC*, and carry a poor prognosis [24]. It remains to be seen if mechanisms of 2HG accumulation unrelated to *IDH* mutation exist in gliomas as well.

It is known that 2HG is primarily derived from glutamine in mutant *IDH* gliomas. Glutamine is hydrolyzed by glutaminase to produce glutamate, which is subsequently converted to  $\alpha$ -KG [3,25]. *MYC* is known to regulate glutamine utilization and glutaminase protein expression [26], and mutant *IDH* gliomas are known to have an increased expression of *MYC* [27]. Interestingly, we found less accumulation of Glx (Glu + Gln) in the mutant *IDH* gliomas ( $p < 0.005$ , Figure 3), suggesting that glutamine consumption is contributing to the accumulation of  $\alpha$ -KG and ultimately 2HG (Figure 1) in these tumors.

2HG acts as a competitive antagonist of  $\alpha$ -KG, causing inhibition of  $\alpha$ -KG-dependent dioxygenases. These include



**Figure 3 2HG is accumulated in mutant *IDH* gliomas.** **A)** Comparisons of amount of metabolites in mutant *IDH* and wild-type *IDH* gliomas show markedly higher accumulation of 2-HG (median 5.007 mM vs. 0.000 mM, Mann-Whitney test,  $p = 0.0002$ ) and lower concentrations of Glx ( $p < 0.05$ ) in mutant *IDH* gliomas. **B)** ROC curve analysis revealed an optimal cutoff of 1.489, with a sensitivity of 100.0% and specificity of 72.2%. 2HG was detectable in all mutant *IDH* gliomas, whereas in 10 out of 27 (37.0%) wild-type *IDH* gliomas, 2HG was not detectable (2HG = 0) ( $p = 0.0003$ , chi-squared test). Five out of 27 (10.3%) wild-type *IDH* gliomas yielded a 2-HG concentration higher than 1.489 mM.



**Figure 4 Longer overall survival in high 2HG glioma patients.**

The overall survival was significantly longer in glioma patients with high accumulation of 2HG (2HG >1.489) compared with low accumulation ( $p = 0.0401$ , Kaplan-Meier analysis).

the JmJc domain-containing histone demethylases (KDMs), which cause histone demethylation [13-15], and the ten-eleven translocation (TET) family of DNA hydroxylases, which cause DNA demethylation [16,15]. This was consistent with data from the The Cancer Genome Atlas (TCGA) database, in which the proneural subgroup of glioblastoma was found to be enriched with *IDH* mutations and display hypermethylation in a large number of loci [28]. A recent report has shown the stimulation of HIF prolyl hydroxylases by (R) enantiomer of 2HG in mutant *IDH* immortalized astrocytes leads to a reduced level of HIF, but enhanced proliferation [29].

There are still others who hypothesize that mutant *IDH* is not tumorigenic, but actually makes tumor cells susceptible to death, evidenced by the longer survival of patients with *IDH* mutant glioma patients [30]. Mutant *IDH1* and 2HG were shown to induce oxidative stress, cell-killing autophagy and apoptosis in a cell type specific manner [31]. New evidence suggests that *IDH1* mutation inhibits the growth of glioma cells via GSH inhibition and generation of reactive oxygen species (ROS) [32]. This study, as well as previous MRS [10] and metabolomic [11] studies have shown that GSH is depleted in mutant *IDH* gliomas.

At least 8 different mutations of *IDH1* and *IDH2* are known in gliomas, at the *IDH1* R132 and *IDH2* R172 loci. 2HG can be detected in gliomas *in vitro* by mass spectrometry or *in vivo* by MRS. One of the proposed advantages of detecting 2HG is that it would provide a screening for all mutations of *IDH1* and *IDH2*, as all *IDH* mutations that are known to produce 2HG [33].

The 2HG molecule contains five nonexchangeable protons, giving rise to multiplets at three locations on 3 T MRS: approximately 4.02, 2.25, and 1.90 ppm (Figure 2) [5]. The multiplet at 2.25 ppm is larger than the other 2HG multiplets. The detection of this multiplet is complicated by the spectral overlap of Glu (2.43 ppm), Gln

(2.34 ppm), and GABA (2.28 ppm) [34]. Direct detection of the multiplet at 1.90 ppm is difficult due to its proximity to NAA resonance at 2.01 ppm. Finally, the multiplet at 4.02 is partially overlapped with Cr (3.92 ppm), PCr (3.94 ppm), Ins (4.06 ppm), lactate (4.1 ppm) and free Cho (4.05 ppm) [5].

A false-positive rate of approximately 22% was observed by Pope et al. using the short-echo MRS with TE at 30 ms for the detection of 2HG [10]. This false-positive rate can be reduced by using long-echo MRS with TE at 97 ms with the use of three-dimensional volume-localized basis (VLB) spectra, which has been shown to be optimal for detection of 2HG [5,6]. A comparative study of PRESS sequences at short- (35 ms) and long- TE (97 ms) found long- TE to be superior for the following reasons: 1) it permits a more favorable voxel localization, and 2) it produces a well-defined narrow 2HG signal at 2.25 ppm, thereby leading to improved differentiation between 2HG and Glu, Gln, and GABA signals. Spectral fitting of PRESS data at TE =97 ms was effective in minimizing the effect of macromolecule signals [5]. Five (18.5%) wild-type *IDH* gliomas in this study were found to have high 2HG accumulation of more than 1.489 mM. Further analysis of these specimens by either mass spectrometry or *ex vivo* MRS is needed to determine whether these results could be attributed to false positive readouts.

Unambiguous detection of 2HG in mutant *IDH* glioma was achieved by 2D correlation spectroscopy (COSY) [4,7,8] and J-difference spectroscopy [4]. However, these methods are less available clinically and involve longer acquisition time; 2D correlation MRS involves complex quantification and has less sensitivity [23]. We achieved 100% sensitivity of 2HG detection by short-echo MRS with modulation of 2HG resonances by spectral fitting. Less acquisition time enabled glioma patients, even those with relatively poor performance status, to undergo analysis. The biggest advantage of detecting 2HG by MRS is that it provides an opportunity for pre-surgical, non-invasive detection of 2HG, thus reliably predicting *IDH* status of gliomas before surgery. There is increasing interest that mutant *IDH* patients may benefit from extensive surgery [35,36]. Also, 2HG is known to degrade after formalin fixation and paraffin embedding [12]. *Ex vivo* assessment of 2HG by MRS or mass spectrometry enable the analysis of homogeneous tumor tissue, but sample degradation and the necessity for treating tissues with reagents pose problems [23].

2HG detection by *in vivo* MRS may be utilized to evaluate response to glioma treatments. *IDH* mutations are known to be very tumor-cell-specific [37], and 2HG accumulation is found to be increased in tumor tissues compared to surrounding tissue. This leads to the notion that 2HG will not be assessable after surgical removal of

a majority of the tumor. However, gliomas are pathologically known to be very infiltrative tumors, with individual glioma cells extending deep into adjacent brain tissues [38]. If 2HG can be detected in adjacent brain tissues by MRS, gliomas can be evaluated serially even after surgical removal of a majority of the tumor. Other metabolites such as Cho, Gln, Glu, lactate, NAA and Cr can be detected in conjunction with 2HG, and this metabolic profile may be utilized to characterize tumor aggressiveness after chemotherapy and radiotherapy, at relapse and may even predict outcome [39].

Potent inhibitors of mutant IDH1 have been developed and are implicated in clinical trials in the United States. *In vitro* studies analyzing 2HG have shown a reduction of 2HG after usage of these inhibitors [40-42]. 2HG analysis by MRS would be an appropriate method to determine biological response of this drug in glioma patients.

## Conclusions

Increasing evidence suggests that 2HG is an important oncometabolite in mutant *IDH* gliomas. *In vivo* MRS has been shown to effectively measure 2HG and predict IDH status preoperatively in WHO grade II and grade III glioma patients. We found 2HG to be a positive prognostic factor in these gliomas. Further studies are warranted for other possible mechanisms of 2HG accumulation in gliomas.

## Additional file

**Additional file 1: No survival difference between mutant *IDH* glioma patients with high vs. low 2HG accumulation.** No difference in survival between mutant *IDH* glioma patients with high 2HG accumulation (2HG >5.077 mM) vs. low 2HG accumulation was noted ( $p=0.8815$ ). Median survival has not been reached in either group.

## Abbreviations

2HG: 2-hydroxyglutarate; 2-HGDH: 2-hydroxyglutarate dehydrogenase; 3 T: 3 tesla;  $\alpha$ -ketoglutarate:  $\alpha$ -KG; Cho: Choline; COSY: 2D correlation spectroscopy; Cr: Creatine; DNA: Deoxyribonucleic acid; GABA:  $\gamma$ -aminobutyric acid; Gln: Glutamine, Glu, glutamate; Glx: Glutamine and glutamate; GPC: Glycerophosphocholine; GSH: Glutathione; IDH: Isocitrate dehydrogenase; IHC: Immunohistochemistry; Ins: Myo-inositol; MRI: Magnetic resonance imaging; MRS: Magnetic resonance spectroscopy; NAA: N-acetylaspartate; NAAG: N-acetylaspartylglutamate; PC: Phosphocholine; PCr: Phosphocreatine; PRESS: Point-resolved spectroscopic sequence; ROC: Receiver operating characteristic; ROS: Reactive oxygen species; SD: Standard of deviation; S/R: Signal-to-noise ratio; SVMRS: Single voxel MRS; TCGA: The Cancer Genome Atlas; tCho: Total choline, tCr, total creatine; TET: Ten-eleven translocation; tNAA: Total NAA; VLB: Volume-localized basis; VOI: Volume of interest; WHO: World Health Organization.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

MN and HI designed the study; HI optimized spectral analysis for 2HG quantification; TN and KO performed the imaging; MN and HI performed metabolite analysis; AK and HT made pathological diagnoses; RO performed IHC and DNA sequencing; TK, RO, AH, and YT assessed patient survival; MN

and HI wrote the manuscript; TN and YF approved the study design. All authors read and approved the final manuscript.

## Acknowledgements

We acknowledge Drs. Kimihiko Nakamura, Taro Nishikawa, Shinya Jinguji and others for help with imaging. We acknowledge Joel Spencer for help with language editing.

## Author details

<sup>1</sup>Department of Neurosurgery, Brain Research Institute, University of Niigata, Niigata, Japan. <sup>2</sup>Center for Integrated Brain Sciences, Brain Research Institute, University of Niigata, Niigata, Japan. <sup>3</sup>Department of Pathology, Brain Research Institute, University of Niigata, Niigata, Japan.

Received: 22 August 2014 Accepted: 22 October 2014

Published online: 07 November 2014

## References

1. Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 455:1061–1068, doi:10.1038/nature07385
2. Yan HPD, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 360:765–773, doi:10.1056/NEJMoa0808710
3. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liao LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 462:739–744, doi:10.1038/nature08617
4. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG (2012) Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. *Sci Transl Med* 4:116 ra4 1–10 doi:10.1126/scitranslmed.3002693
5. Choi C, Ganji S, Hulsey K, Madan A, Kovacs Z, Dimitrov I, Zhang S, Pichumani K, Mendelsohn D, Mickey B, Malloy C, Bachoo R, DeBerardinis R, Maher E (2013) A comparative study of short- and long-TE (1)H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. *NMR Biomed* 26:1242–1250, doi:10.1002/nbm.2943
6. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen JM, Marin-Valencia I, Pascual JM, Madden CJ, Mickey BE, Malloy CR, Bachoo RM, Maher EA (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. *Nat Med* 18:624–629, doi:10.1038/nm.2682
7. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, Bourne G, Berger MS, Chang SM, Cha S, Nelson SJ (2012) Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. *Sci Transl Med* 4:116ra5 1–10 doi:10.1126/scitranslmed.3002796
8. Esmaeili MVR, Bathen TF (2013) 2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping. *Transl Oncol* 6:92–98, doi:10.1593/tlo.12424
9. Lazovic J, Soto H, Piccioni D, Lou JR, Li S, Mirsadraei L, Yong W, Prins R, Liao LM, Ellingson BM, Cloughesy TF, Lai A, Pope WB (2012) Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. *Neuro Oncol* 14:1465–1472, doi:10.1093/neuonc/nos258
10. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liao LM (2012) Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. *J Neurooncol* 107:197–205, doi:10.1007/s11060-011-0737-8
11. Reitman ZJJG, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H (2011) Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. *Proc Natl Acad Sci U S A* 108:3270–3275, doi:10.1073/pnas.1019393108
12. Sahn F, Capper D, Pusch S, Balss J, Koch A, Langhans CD, Okun JG, von Deimling A (2012) Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. *Brain Pathol* 22:26–31, doi:10.1111/j.1750-3639.2011.00506.x

13. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, McDonough MA, King ON, Clifton IJ, Klose RJ, Claridge TD, Ratcliffe PJ, Schofield CJ, Kawamura A (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. *EMBO Rep* 12:463–469, doi:10.1038/embor.2011.43
14. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. *Nature* 483:474–478, doi:10.1038/nature10860
15. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. *Cancer Cell* 19:17–30, doi:10.1016/j.ccr.2010.12.014
16. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley JA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* 18:553–567, doi:10.1016/j.ccr.2010.11.015
17. Provencher S (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. *Magn Reson Med* 30:672–679, doi:10.1002/mrm.1910300604
18. Takado Y, Igarashi H, Terajima K, Shimohata T, Ozawa T, Okamoto K, Nishizawa M, Nakada T (2011) Brainstem metabolites in multiple system atrophy of cerebellar type: 3.0-T magnetic resonance spectroscopy study. *Mov Disord* 26:1297–1302, doi:10.1002/mds.23550
19. Louis DNOH, Wiestler OD, Cavenee WK (2007) WHO Classification of Tumours of the Central Nervous System. IARC, Lyon
20. Ashraf S, Noguera NI, Di Giandomenico J, Zaza S, Hasan SK, Lo-Coco F (2013) Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia. *Ann Hematol* 92:1319–1323, doi:10.1007/s00277-013-1868-0
21. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. *Acta Neuropathol* 118:599–601, doi:10.1007/s00401-009-0595-z
22. Struys EA, Salomons GS, Achouri Y, Van Schaftingen E, Grosso S, Craigen WJ, Verhoeven NM, Jakobs C (2005) Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. *Am J Hum Genet* 76:358–360, doi:10.1086/427890
23. Andronesi OC, Rappalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, Sorensen AG, Rosen BR (2013) Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. *J Clin Invest* 123:3659–3663, doi:10.1172/JCI67229
24. Terunuma A, Putluri N, Mishra P, Mathe EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS, Karoly ED, Chan K, Samanta S, Prieto D, Hsu TY, Kurlay SJ, Putluri V, Sonavane R, Edelman DC, Wulff J, Starks AM, Yang Y, Kittles RA, Yfantis HG, Lee DH, Ioffe OB, Schiff R, Stephens RM, Meltzer PS et al (2014) MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. *J Clin Invest* 124:398–412, doi:10.1172/JCI71180
25. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, Dang CV, Riggins GJ (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. *Cancer Res* 70:8981–8987, doi:10.1158/0008-5472.CAN-10-1666
26. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature* 458:762–765, doi:10.1038/nature07823
27. Oda YOB, Bell WR, Eberhart CG, Rodriguez FJ (2013) cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathological features and outcome. *J Neurooncol* 115:249–259, doi:10.1007/s11060-013-1221-4
28. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K, Cancer Genome Atlas Research N (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* 17:510–522, doi:10.1016/j.ccr.2010.03.017
29. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, Travins J, Weiss S, Looper R, Ligon KL, Verhaak RG, Yan H, Kaelin WG Jr (2012) Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. *Nature* 483:484–488, doi:10.1038/nature10898
30. Zhu J, Zuo J, Xu Q, Wang X, Wang Z, Zhou D (2011) Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. *Med Hypotheses* 76:602–603, doi:10.1016/j.mehy.2011.01.011
31. Gilbert MR, Liu Y, Neltner J, Pu H, Morris A, Sunkara M, Pittman T, Kyprianou N, Horbinski C (2014) Autophagy and oxidative stress in gliomas with IDH1 mutations. *Acta Neuropathol* 127:221–233, doi:10.1007/s00401-013-1194-6
32. Shi J, Zuo H, Ni L, Xia L, Zhao L, Gong M, Nie D, Gong P, Cui D, Shi W, Chen J (2013) An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation. *Neurol Sci Advance*, online publishing doi:10.1007/s10072-013-1607-2
33. Rakheja D, Medeiros LJ, Bevan S, Chen W (2013) The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms. *Front Oncol* 3:1–9, doi:10.3389/fonc.2013.00169
34. Govindaraju VYK, Maudsley AA (2000) Proton NMR chemical shifts and coupling constants for brain metabolites. *NMR Biomed* 13:129–153, doi:10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V
35. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, McCutcheon IE, Cahill DP (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. *Neuro Oncol* 16:81–91, doi:10.1093/neuonc/not159
36. Dunn GP, Andronesi OC, Cahill DP (2013) From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. *Neurosurg Focus* 34(E2):1–15, doi:10.3171/2012.12.FOCUS12355
37. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD (2009) A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. *Biochem Biophys Res Commun* 390:547–551, doi:10.1016/j.bbrc.2009.10.001
38. Claes A, Idema AJ, Wesseling P (2007) Diffuse glioma growth: a guerilla war. *Acta Neuropathol* 114:443–458, doi:10.1007/s00401-007-0293-7
39. Quon HBB, Alexander A, Murtha A, Abdulkarim B, Fulton D, Smerdely M, Johnson M, Urtasun R, Patel S, Ghosh S, Roa W (2011) Changes in serial magnetic resonance spectroscopy predict outcome in high-grade glioma during and after postoperative radiotherapy. *Anticancer Res* 31:3559–3565, doi:http://ar.iarjournals.org/content/31/10.toc
40. Davis MPR, Popovici-Muller J, Gross S, Thorne N, Salituro F, Fantin V, Straley K, Su M, Dang L, Simeonov A, Shen M, Boxer MB (2012) ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. *Probe Reports from the NIH Mol Libr Progr*, doi:http://www.ncbi.nlm.nih.gov/books/NBK153220/
41. Popovici-Muller J, Saunders JO, Salituro FG, Travins JM, Yan S, Zhao F, Gross S, Dang L, Yen KE, Yang H, Straley KS, Jin S, Kunii K, Fantin VR, Zhang S, Pan Q, Shi D, Biller SA, Su SM (2012) Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HgIn Vivo. *ACS Med Chem Lett* 3:850–855, doi:10.1021/ml300225h
42. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernysky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science* 340:626–630, doi:10.1126/science.1236062

doi:10.1186/s40478-014-0158-y

**Cite this article as:** Natsumeda et al.: Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. *Acta Neuropathologica Communications* 2014 **2**:158.